Allowing bedside nurses to independently order testing for C difficile was tied to faster test results.
The drug marks the first fecal microbiota therapy that can be taken orally.
The Cochrane Review analysis finds fecal microbiota transplantation likely leads to a large decrease in recurrent Clostridioides difficile infection compared with antibiotics.
Researchers report that a high dose of a novel oral microbiome-directed therapy prevented recurrent Clostridioides difficile infection.
The expert guidance says antibiotic exposure is the most modifiable risk factor for C difficile infection.
The authors said the findings for the treatment, approved by the FDA in December, are similar to what doctors can expect in clinical practice.
The test order rate per 1,000 patient-days fell from 126.5 in the pre-intervention period to 90.6 in the intervention period, a 28% reduction.
Screening patients for Clostridioides difficile colonization was not useful for preventing C difficile infection, Dutch researchers report.
SER-109, an investigational microbiome therapeutic for treating recurrent Clostridioides difficile infection, was well tolerated and showed clinical benefit.
Approval of Rebyota, made by Ferring Pharmaceuticals, was based on findings from multiple randomized clinical trials.